RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256

Benzinga Newsdesk www.benzinga.com Negative 95.8%

Neg 95.8% Neu 0% Pos 0%

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $260 to $256.